HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells

Differentiation therapy based on all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL) is complicated by the development of differentiation syndrome (DS), which can be fatal. We examined the role of HMGB1 (high-mobility group box 1) in DS u...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lanlan, Chai, Wenwen, Ye, Fanghua, Yu, Yan, Cao, Lizhi, Yang, Minghua, Xie, Min, Yang, Liangchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432337/
https://www.ncbi.nlm.nih.gov/pubmed/28404891
http://dx.doi.org/10.18632/oncotarget.15432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432337/
https://www.ncbi.nlm.nih.gov/pubmed/28404891
http://dx.doi.org/10.18632/oncotarget.15432

Ejemplares similares